ROSA Total Knee Post Market Study EMEA
| Condition | Knee Pain, Chronic Osteoarthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus or Flexion Deformities |
|---|---|
| Phase | N/A |
| Sponsor | Zimmer Biomet |
| Status | Completed |
| Enrollment | 252 participants |
| Interventions | Device: Persona Total Knee, Device: NexGen Total Knee, Device: Vanguard Total Knee |
| Start date | Dec 15, 2020 |
| Completion date | Aug 22, 2025 |
| Results posted | Jan 21, 2026 |
Summary
This is a prospective, multicenter clinical study designed to facilitate the collection and evaluation of surgical workflow efficiency, patient pain and function outcome and adverse events data. This study might include Persona, Nexgen and Vanguard product families using the ROSA Total Knee Robotic system or conventional instrumentation. The primary objective is to evaluate the accuracy of implant alignment for ROSA Total Knee robotic instrumentation compared to conventional instrumentation.
Alignment Accuracy
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company